TMDX TransMedics Group, Inc.
Q3 2025 10-Q
Filed: Oct 29, 2025Period ending Sep 30, 2025
Health Care
Electromedical & Electrotherapeutic ApparatusSEC EDGAR TransMedics Group, Inc. (TMDX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: Prolonged U.S. government shutdown impacting FDA, FAA, SEC operations and causing aviation staffing shortages
- • Most updated regulatory risk: FDA review and approval timelines may extend due to funding, staffing, policy changes affecting product launches
Quarterly Financial SummaryXBRL
Revenue
$144M
▲ +32.2% YoY▼ -8.6% QoQ
Net Income
$24M
▲ +476.8% YoY▼ -30.3% QoQ
Gross Margin
58.8%
▲ +286bp YoY▼ -257bp QoQ
Operating Margin
16.2%
▲ +1259bp YoY▼ -704bp QoQ
Net Margin
16.9%
▲ +1303bp YoY▼ -527bp QoQ
ROE
6.8%
Total Assets
$946M
EPS (Diluted)
$0.66
▲ +500.0% YoY▼ -28.3% QoQ
Operating Cash Flow
$70M
▲ +914.6% YoY▼ -24.1% QoQ
Source: XBRL data from TransMedics Group, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on TransMedics Group, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.